Description
Seeking adults with non-small cell lung cancer (NSCLC) that has spread despite chemotherapy and immunotherapy and can't be treated with surgery or radiation for a study of an investigational therapeutic cancer vaccine designed to activate cells in the body that fight cancers.
Overview
Participants in this study will first be screened to confirm their cells contain the HLA-A2 receptor. During the study treatment period, participants will be randomly selected to get either the investigational drug or Docetaxel chemotherapy once every 3 weeks for 6 cycles and then once every 2 months for cycles the remaining cycles.
What we're hoping for
We are studying an investigational therapeutic cancer vaccine to activate cells in the body that fight cancers for non-small cell lung cancer (NSCLC) that did not respond or returned after a first treatment of chemotherapy and immunotherapy.
Additional Information
ClinicalTrials.gov Identifier: NCT06472245